Joseph Patti
Director/Miembro de la Junta en ARMATA PHARMACEUTICALS, INC. .
Fortuna: - $ al 30/04/2024
Cargos activos de Joseph Patti
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ARMATA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 09/05/2019 | - |
Independent Dir/Board Member | 09/05/2019 | - | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Director/Miembro de la Junta | 01/03/2019 | - |
JP Biotech Advisors, Inc. | Presidente | 01/02/2018 | - |
Historial de carrera de Joseph Patti
Antiguos cargos conocidos de Joseph Patti.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Director/Miembro de la Junta | 01/06/2022 | 14/09/2023 |
Director Ejecutivo | 01/06/2022 | 14/09/2023 | |
Presidente | 01/06/2022 | 14/09/2023 | |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Director/Miembro de la Junta | 01/08/2019 | 01/07/2021 |
Director Ejecutivo | 01/08/2019 | 01/07/2021 | |
Presidente | 01/11/2018 | 01/08/2019 | |
Presidente | 01/08/2019 | 01/07/2021 | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Miembro de la Junta | 01/10/2014 | 01/02/2018 |
Director Ejecutivo | 01/10/2014 | 01/02/2018 | |
Corporate Officer/Principal | 12/11/2012 | 01/10/2014 | |
Presidente | 01/10/2014 | 01/02/2018 | |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Director/Miembro de la Junta | 01/01/2012 | 01/01/2015 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Director/Miembro de la Junta | 01/01/1998 | 01/01/2005 |
Director Técnico/Científico/I+D | 01/05/1994 | 01/02/2012 | |
Fundador | 01/05/1994 | 01/02/2012 | |
Institute of Biosciences & Technology | Corporate Officer/Principal | 01/01/1994 | 01/01/1998 |
░░░░░ ░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ | - | - |
Formación de Joseph Patti.
University of Pittsburgh | Undergraduate Degree |
The University of Alabama at Birmingham | Doctorate Degree |
The University of Miami Leonard M. Miller School of Medicine | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 15 |
Operativa
Director/Board Member | 7 |
President | 5 |
Chief Executive Officer | 4 |
Sectorial
Health Technology | 7 |
Consumer Services | 6 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
VAXART, INC. | Health Technology |
ARMATA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 7 |
---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Health Technology |
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Commercial Services |
JP Biotech Advisors, Inc. | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Technology Services |
- Bolsa de valores
- Insiders
- Joseph Patti
- Experiencia